BioCryst/Roche's psoriasis drug enters Ph II
Alabama, USA-based BioCryst Pharmaceuticals and Swiss drug major Roche have initiated the first Phase II study to evaluate their co-developed drug candidate BCX-4208/R3421. This clinical trial, led by Roche, is designed to evaluate BCX-4208 in patients with moderate-to-severe plaque psoriasis.
The orally-available small-molecule inhibitor of purine nucleoside phosphorylase (PNP) is an enzyme that is essential for the proliferation of activated T cells. With its novel mechanism of action, BCX- 4208 has the potential to address unmet medical needs across a broad spectrum of autoimmune diseases as well as in the area of acute transplant rejection, the firm stated.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze